Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Assessing the Impact of Hemodynamic Monitoring with CardioMEMS on Heart Failure Patients: A Cost-effectiveness Analysis

Version 1 : Received: 3 January 2023 / Approved: 6 January 2023 / Online: 6 January 2023 (04:41:21 CET)
Version 2 : Received: 17 September 2023 / Approved: 18 September 2023 / Online: 19 September 2023 (05:23:15 CEST)

How to cite: Codina, P.; Vicente Gómez, J.A.; Hernández Guillamet, G.; Ricou Ríos, L.; Carrete, A.; Vilalta, V.; Estrada, O.; Ara, J.; Lupón, J.; Bayés-Genís, A.; López Seguí, F. Assessing the Impact of Hemodynamic Monitoring with CardioMEMS on Heart Failure Patients: A Cost-effectiveness Analysis. Preprints 2023, 2023010116. https://doi.org/10.20944/preprints202301.0116.v1 Codina, P.; Vicente Gómez, J.A.; Hernández Guillamet, G.; Ricou Ríos, L.; Carrete, A.; Vilalta, V.; Estrada, O.; Ara, J.; Lupón, J.; Bayés-Genís, A.; López Seguí, F. Assessing the Impact of Hemodynamic Monitoring with CardioMEMS on Heart Failure Patients: A Cost-effectiveness Analysis. Preprints 2023, 2023010116. https://doi.org/10.20944/preprints202301.0116.v1

Abstract

Background: Real-time remote monitoring of pulmonary artery pressures has previously shown to reduce heart failure (HF) related hospitalisations and to improve quality of life of selected HF patients. The value of CardioMEMS in Southern Europe, where healthcare costs are significantly lower, remains uncertain. Objective: To evaluate the cost-effectiveness of the CardioMEMS HF system in the Spanish healthcare setting. Methodology: This single-centre study included 35 HF patients with a CardioMEMS device (treatment group) and compared them with similar patients receiving standard HF treatment (control group). The Propensity Score Matching method was used and the comparators were found using the variables age, sex, New York Heart Association class, left ventricular ejection fraction, and diabetes mellitus. Cost-effectiveness was measured as the incremental cost per quality-adjusted life year gained. Results: The CardioMEMS HF system outperformed usual management with a net monetary value difference of 2,731€ per patient at 1 year. The incremental cost per quality-adjusted life year gained was 15,896€. Results were consistent in the sensitivity analyses performed. Conclusion: This analysis suggests that remote monitoring of pulmonary artery pressure with CardioMEMS HF system is a cost-effective strategy in the Spanish healthcare setting.

Keywords

cost-effectiveness evaluation; heart failure; telemonitoring; pulmonary artery pressure; hemodynamic monitoring

Subject

Medicine and Pharmacology, Cardiac and Cardiovascular Systems

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.